60% relief, GSK multiple myeloma new drug results are excellent
60% relief, GSK multiple myeloma new drug results are excellent
December 12, 2017 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, GlaxoSmithKline (GSK) published excellent data on its new drug GSK2857916 in clinical trials at the American Society of Hematology (ASH). In patients with treated multiple myeloma, this new drug monotherapy achieved a 60% response rate.
Multiple myeloma is the second most common blood cancer in the United States and is generally considered to be a disease that can be controlled by treatment but is incurable. Over time, the disease slowly becomes resistant to existing therapies and becomes refractory. Therefore, patients are also in urgent need of new treatment options.
GSK2857916 brought by GSK is such an innovative treatment that is expected to treat multiple myeloma. This is an antibody drug conjugate made by coupling a humanized BCMA monoclonal antibody to the cytotoxic drug MMAF (monomethyl auristatin-F) via a linker. A month ago, it was awarded a breakthrough therapy by the US FDA.
In a clinical trial called DREAMM -1, the researchers enrolled patients with relapsed/refractory multiple myeloma and assessed the safety (primary endpoint), relief of GSK2857916 in this patient population. Rate, pharmacokinetics, and immunogenicity. It is worth mentioning that these patients have received a large number of treatments, and 57% of patients have received at least 5 treatments. For them, the treatment options are extremely limited.
Fortunately, in this patient population, GSK2857916 achieved a 60% response rate (95% CI: 42.1% - 76.1%) and a median progression-free survival (PFS) of 7.9 months (95% CI: 3.1). Month - cannot be estimated). The most common side effects were corneal problems (63%) and thrombocytopenia (57%), with no limited dose of toxic events.
â–² Dr. Axel Hoos, Senior Vice President, Oncology Research and Development, GSK (Source: GSK Official Website)
“There are limited options for further treatment of patients participating in DREAMM-1, and we are very excited about the response rates seen in this trial,†said Dr. Axel Hoos, Senior Vice President, Oncology Research, GSK. “GSK2857916 is our revolutionary tumor. Learning the leading products in the new drug pipeline, we plan to rapidly advance its development projects and launch key monotherapy and combination therapy trials in 2018."
At this year's ASH Annual Meeting, we heard a lot of good news about the BCMA target (see other reports from WuXi PharmaTech today). Here we also wish that more therapies will come out smoothly for the benefit of patients with multiple myeloma.
Reference materials:
[1] GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting
[2] GSK offers encouraging data on BCMA-targeting armed antibody, setting stage for a return to late-stage cancer studies
Point Of Care Testing POCT
GENEDIAN iRapid 4 POC RT-PCR Detection System is a fully automatic integrated system with simplified operation, easy to achieve "rapid read results", fully enclosed detection, safe and pollution-free features. Configured with GENEDIAN POC SARS-CoV-2 Nucleic Acid Detection Kit, the 4-well system is able to run independently as well as run four different parameters at the same time.
Pcr System,Pcr Detection System,Real Time Pcr System,Quantitative Pcr Detection System
Hangzhou DIAN Biotechnology Co., Ltd. , https://www.dianbiotech.com